Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.
暂无分享，去创建一个
Y. Bang | E. Raymond | A. Vinik | Xin Huang | S. Faivre | P. Metrakos | P. Ruszniewski | P. Niccoli | Jen‐Shi Chen | D. Castellano | Se-Hoon Lee | P. Hammel | J. Valle | J. Raoul | J. Seitz | I. Borbath | Denis Smith | J. Ishak | C. L. Bohas | J. Chen | S. Patyna